Use of an albendazole bolus against gastrointestinal nematode infections in first year cattle

Thirty first year grazing calves were allocated to two groups of 15 calves each on the basis of bodyweight and were administered albendazole boli or placebo boli, respectively, 30 days after turnout. The albendazole bolus prevented the nematode egg output almost completely for about 4 months, whereas the controls had mean egg counts of up to 206. Pepsinogen concentrations were significantly higher in the control group and reached mean values of 3055 mU tyrosine compared to less than 1000 mU tyrosine in the albendazole treated group after bolus administration. Pasture contamination with trichostrongylid larvae was markedly lower on pastures of the albendazole group than on the controls. Mean weight gains were significantly higher in the albendazole group than in the controls with a difference of 10.7 kg per animal at the end of the season.     

Effects of ivermectin and fenbendazole in strategic treatment of gastrointestinal nematode infections in cattle

Four groups of 18 beef calves each were used to evaluate effects of different treatments on parasite control and weight gains. The investigation extended from November 1986 (weaning) to October 1987. Group-1 calves were treated with ivermectin (200 micrograms/kg of body weight, SC) at approximately 6-week intervals for a total of 8 treatments; group-2 calves were given the same dosage of ivermectin by the same route of administration as group-1 calves in November, March, and July; group-3 calves were given fenbendazole paste (5 mg/kg, PO) at the same times as group-2 calves; and group-4 calves served as untreated controls with provision for ivermectin salvage treatment. All groups grazed on individual pairs of larval-contaminated, 1.6-ha pastures. Highest (P less than 0.05) initial worm counts in fall tracer calves were found in group 3 (Ostertagia ostertagi and Trichostrongylus axei adults) and group 4 (O ostertagi and Haemonchus adults). Fecal egg counts of group-1 calves were low throughout the experiment and pasture larval counts remained negligible after July. Egg counts and larval counts of other groups remained higher into summer. Worm counts, including O ostertagi inhibited early fourth-stage larvae (EL4), were highest (P less than 0.05) in groups-3 and -4 spring tracer calves; numbers of O ostertagi EL4 were similarly high in groups 2, 3, and 4; and T axei counts were highest (P less than 0.05) in groups-3 and -4 yearlings slaughtered in spring. Liveweights of group-1 calves were greater (P less than 0.05) than in other groups from March 2 to October, and by July 2, group-2 calves had a liveweight advantage over group-4 calves. Group-3 calves had the lowest rate of gain from March to July and mean liveweight of the group was less (P less than 0.05) than in all other groups from April to October. Only minimal worm numbers were recovered from groups-1 or -2 calves in October. Large numbers of O ostertagi and T axei were recovered from group-4 calves and O ostertagi from group-3 calves. A few calves in groups 3 and 4, but particularly in group 4, were affected by type-II disease (chronic to acute gastritis caused by maturation and emergence of previously inhibited larvae) from August to October. Final mean liveweights in descending order were 365 kg in group 1, 328 kg in group 2, 316 kg in group 4, and 281 kg in group 3.     

Prophylactic efficacy of an ivermectin sustained-release bolus against challenge exposure with gastrointestinal and pulmonary nematode infective larvae in calves

Twelve Holstein calves were used to determine the prophylactic efficacy of ivermectin against challenge exposure with gastrointestinal and pulmonary nematodes. Two groups of 6 calves (mean body weight, 205 kg) each were formed by restricted randomization according to body weight. Group-1 calves served as nonmedicated controls. Each calf of group 2 was orally given one prototype sustained-release bolus designed to deliver ivermectin at a continuous daily dose of 8 mg. Third-stage nematode infective larvae were given to the calves on posttreatment days 28 and 42. The calves were euthanatized 77 or 78 days after treatment. Ivermectin was 100% effective (P less than 0.05) in preventing the establishment of infection by Haemonchus placei, Ostertagia ostertagi, Cooperia spp (C punctata, C oncophora, C surnabada), Nematodirus helvetianus, Oesophagostomum radiatum, and Dictyocaulus viviparus and was greater than 99% effective against Trichostrongylus axei. Incidental infection by Trichuris spp was reduced by 94% (P = 0.08).     

Topically applied ivermectin and Cooperia infections in cattle

Extract

I have read with some interest a recent report in this journal⁽¹⁾ that topically applied ivermectin (Ivomec Pour-On, MSD Agvet NZ Ltd) was found to be largely ineffective against Cooperiu infection in cattle.     

Efficacy of ivermectin against induced gastrointestinal nematode infections in goats

The efficacy of ivermectin (0.08 per cent w/v oral solution) at different dose levels was evaluated against induced infections of adult Haemonchus contortus (21 days old) and Trichostrongylus colubriformis (21 days old) and fourth stage larvae of Oesophagostomum columbianum (17 days old), Ostertagia circumcincta (five days old) and Strongyloides papillosus (five days old). Twenty-five Boergoats (mutton goats) were randomly allocated by bodyweight within each sex to an untreated control group and four ivermectin treatment groups; ivermectin was administered at either 25, 50, 100 or 200 micrograms/kg orally, once. The goats were killed and processed for worm recovery 25 to 27 days after treatment. At 25 micrograms/kg the efficacy of ivermectin varied from 43 per cent for adult T colubriformis to more than 99 per cent for fourth larval stage O columbianum. Ivermectin at 50 micrograms/kg or higher was 99 per cent or more effective against all induced parasite infections with the exception of ivermectin at 50 micrograms/kg against S papillosus (97 per cent). For all parasites there was a statistically significant (P less than 0.05) difference between the control group and the pooled treated groups. No adverse reactions to ivermectin treatment were observed in the goats.     

Effects of the use of a morantel sustained release bolus in first and second year grazing cattle

In an experiment carried out in 1981 and 1982, the effect of the use of a morantel sustained release bolus (Paratect bolus) on the weight gain and a number of parasitological parameters of cattle was studied. In the first year 42 calves were divided into 3 equal groups, one group was kept outside and treated with a bolus (B), the second group was kept outside and was not treated (C), while the third group remained indoors (I). Groups B and C were grazed separately on contaminated pasture. During the first months Group B had a negligible egg output. The egg output in the controls was much higher and in mid-August they had to be treated for parasitic gastroenteritis. At the end of the grazing season the advantage in weight gain of Group B was 20 kg compared with the controls. During the housing period the growth in the 3 groups was not significantly different. At the start of the second grazing season half the animals of Groups B, C and I received a bolus (Groups BB, CB and IB). The other half remained untreated (BC, CC and IC). The animals treated with a bolus in 1982 gained significantly more weight (64 g/day) than untreated animals. Heifers turned out for the first time (IB and IC) showed much less weight gain than heifers in their second grazing season. The heifers which had previously grazed in 1981 had a very low egg output compared with Groups IB and IC, although the level of egg output of the latter was also not very high (max, almost 40 (eggs per gram (EPG)). In faecal cultures of heifers of Group BC, CB and CC, no Cooperia oncophora-larvae were seen from May onwards, indicating a strong immunity against this species. In Group BB very low numbers of C. oncophora-larvae were observed. In Groups IB and IC, C. oncophora was present during the whole season. At the end of the first season the level of herbage infestation on the control pastures was much higher. In 1982 only slight differences in level of infestation between the pastures were observed. At the start of the season in 1982 serum pepsinogen levels were much higher in the groups which grazed in 1981, compared with the indoor-fed groups. Groups BC and CC had significantly higher levels than Groups BB and CB and all 4 groups always had higher levels than Groups IB and IC.(ABSTRACT TRUNCATED AT 400 WORDS)     

Efficacy of ivermectin administered via sustained-release bolus against gastrointestinal nematodes in cattle

Twelve calves (mean weight, 175.5 kg) were used to confirm efficacy of ivermectin delivered from a prototype sustained-release bolus against naturally acquired gastrointestinal nematodes including early fourth-stage (inhibited) larvae of Ostertagia ostertagi. The calves were allocated by restricted randomization on weight to 1 of 2 groups: controls, to which a placebo bolus was given orally, and treated calves, to which a sustained-release bolus designed to deliver 8 mg of ivermectin/day at a steady rate was given orally. After treatment, the 2 groups were housed in separate pens with concrete flooring. Twenty-eight days after treatment, all calves were euthanatized and necropsied. The ivermectin-treated calves had no larval or adult Ostertagia spp and significantly (P less than 0.01) fewer adult Trichostrongylus axei and adult Cooperia (C oncophora, C punctata and C surnabada) than control calves. Efficacy of ivermectin was greater than 99% for Cooperia spp, and 100% for other parasites. Drug-related adverse reactions were not observed.     

Performance of pigs with mixed nematode infections before and after ivermectin treatment

Ninety crossbred parasitized pigs were used in two controlled experiments to compare performance before and after ivermectin treatment. Four groups of 15 pigs were sequentially infected with 2000 Ascaris suum, 10,000 Oesophagostomum spp. and 10,000 Strongyloides ransomi beginning at average pig weights of either 38 kg (Experiment I) or 14 kg (Experiment II). Two infected groups of pigs were treated with ivermectin on Day 34 (Experiment I) or 37 (Experiment II) of the experiments and all pigs were fed to slaughter weights of approximately 100 kg. Average daily gain (ADG) of heavier ivermectin-treated pigs was greater than that of infected non-treated pigs (P less than 0.03) and feed conversion was numerically greater by 5% (P greater than 0.10). ADG was not different between lighter treated or non-treated pigs, but feed conversion was numerically 4% greater in ivermectin-treated compared to non-treated pigs (P greater than 0.10). No differences existed in carcass dressing percentage among the three groups of heavier pigs, but among the lighter groups ivermectin-treated pigs had a higher dressing percentage (P less than 0.03) than infected non-treated or control pigs. Results of the calculation of production costs based on combined data from the two experiments for the post-treatment period, including feed, drug and maintenance costs, indicate that the production cost for ivermectin-treated pigs was $1.53 per pig less than that for infected non-treated pigs when the cost for each group to attain control pig weights is compared with the actual cost for control pigs.     

The use of a morantel sustained release bolus in the seasonal control of parasitic gastroenteritis in second-season cattle

The efficacy of a morantel sustained release bolus was evaluated during the 1980 summer grazing season in 216 yearling, second-season cattle in nine trials in West Germany. In five trials individual farms were used, in which medicated and control groups could be grazed on adjacent pastures. In four additional trials medicated and control groups were maintained on separate farms where the sites and management practice were matched as far as possible. Faecal worm egg counts, herbage larval counts and weight gain were monitored at regular intervals throughout the season. The faecal output of gastrointestinal nematode eggs was reduced by 55.8 percent in the medicated animals during the period from May to early August, while worm egg counts were equal to that of the control animals during the later part of the season. Herbage larval counts were similar on pastures grazed by medicated and nonmedicated cattle. In the five trials where individual farms were used the average daily weight gains over the entire grazing period were 900 (+/- 222) g/animal/day in the medicated group compared with 826 (+/- 263) g/animal in the nonmedicated cattle, a non-significant advantage. No advantage for the treated over the control groups was detected in the additional 4 trials but this was attributed largely to the difficulty in obtaining comparable groups of animals in comparable grazing conditions in "matching" farms, leading to inter-farm variation.     

Control of induced infestations of adult Amblyomma hebraeum with sustained release ivermectin

The efficacy of ivermectin, administered in a sustained release formulation by intraruminal pumps at approximate daily dose rates of 20, 40 and 60 micrograms/kg, was evaluated in 16 cattle against induced infestations of 3 strains of adult Amblyomma hebraeum. Engorged female ticks were mass-measured and incubated, and reproductive data recorded. There was an increase in mortality of male and female ticks compared to that of controls with increasing daily dose of ivermectin, and a decrease in the number of ticks engorging. Ticks fed on ivermectin-treated cattle had a smaller mass when engorged and laid smaller egg masses, both absolutely and as a proportion of engorged mass. Index of reproduction was reduced 100% at 60 micrograms/kg/day, greater than 99% at 40 micrograms/kg/day and 96% at 20 micrograms/kg/day. Differences occurred between the 3 strains of A. hebraeum used in the study, especially with regard to engorged mass and reproductive variables. Practical implications of the application of sustained release ivermectin for the control of A. hebraeum, specifically with reference to heartwater (Cowdria ruminantium), are discussed.     

Three treatments with ivermectin in year-long control of gastrointestinal nematode parasites of weaner-yearling beef cattle

Four groups of 17 crossbred beef weaners were used in an experiment which extended from 14 November 1985 to 8 October 1986 (328 days). All groups began grazing on separate, contaminated pastures at a stocking rate of 5.3 cattle ha-1 and the different treatments were: Group 1, ivermectin (IVM) injectable X 1 (200 micrograms kg-1) on 14 November only, with provision for individual salvage treatment; Group 2, IVM X 3 on 14 November, 4 February and 2 July; Group 3, IVM X 2 on 14 November and 2 July; Group 4, fenbendazole (FBZ) paste X 2 (5 mg kg-1) on 14 November and 2 July. Pairs of parasite-free tracer calves were grazed on all group pastures for 1 month at the beginning of the experiment (13 November-12 December and in spring (1 April-1 May). Yearling cattle from each group were randomly selected and removed from pasture during spring (n = 2 per group, 3 April) and at the end of the experiment (n = 3 per group, 8 October) for slaughter analysis of worm population characteristics and observation of gross pathology in the abomasum and intestinal tract. At monthly intervals, all cattle were weighed and fecal egg counts, pasture larval counts and plasma pepsinogen values were determined. The results of this investigation demonstrated that three IVM treatments of weaner-yearling beef cattle during year-long grazing, were more effective than a single IVM treatment or two treatments with IVM or FBZ in the enhancement of productivity and protection from the effects of infection with nematode parasites.     

The effectiveness of the new morantel sustained-release trilaminate bolus against gastrointestinal nematode infections in cattle in their first grazing period

The efficacy of a recently developed Morantel-Sustained-Release-Trilaminate-Bolus (Paratect Flex Bolus [PFB]-Pfizer Inc.) against gastrointestinal nematode infections in cattle was assessed by monitoring faecal egg counts (EpG), herbage larval counts, serum pepsinogen levels and liveweight gains in first season calves. In two field trials (1987 and 1988), a PFB-Bolus was administered to two different groups of animals (1987: 15 calves; 1988:13 calves) at turnout (29 May 1987; 26 May 1988), control groups were included. In 1988, 13 calves received for comparison an Oxfendazole-Release-Bolus (Systamex Intervall Bolus [OXF]-Coopers Inc.). All groups were grazed on adjacent but separately fenced pastures throughout the season, until housing (27 October 1987; 15 October 1988). When compared with controls, the PFB-groups showed significantly lower EpG values and consequently, lower herbage larval counts throughout the season in both trials. From day 30 after turnout, the PFB-group had significantly lower serum pepsinogen levels, which reflects the low degree of abomasal damage in these animals. When compared to controls, the PFB-treated animals showed significantly higher weight performances. The mean weight-gain benefit of PFB-treated animals was +12.5 kg (p less than 0.05) and +21.1 kg (p less than 0.005) in 1987 and 1988, resp. No difference occurred between PFB-treated and OXF-treated calves, the latter outperformed the control animals by +21.6 kg (p less than 0.005).     

Evaluation of the morantel sustained release bolus in cows and calves

The efficacy of the morantel sustained release bolus (MSRB) in controlling gastrointestinal parasitism in beef cattle was assessed during the 1982 spring-autumn grazing season. Forty-eight cows and their calves were allotted to three equal groups. One group (T-1) served as a nonmedicated control group. One MSRB was administered to each calf of the T-2 group, and to each cow and calf of the T-3 group at the beginning of the study. The efficacy of the bolus was assessed by comparison of weight gain performance and parasitological data (fecal worm egg counts, herbage larval counts, worm counts from tracer and principal trial calves, and plasma pepsinogen level determinations). Though not statistically significant, treated calves from Group T-2 had a numerical mean weight gain advantage of 2.6 kg, and those from Group T-3 of 4.7 kg, over control calves. Average daily gains (ADG) for the three groups of calves were 0.69, 0.72, and 0.73 kg, respectively. Untreated cows from Group T-2 and treated cows from Group T-3 outperformed the control cows by 12.3 and 7.5 kg, respectively. Fecal worm egg counts from both groups of treated calves were significantly (P less than 0.01) lower than counts from control calves during the entire 169-day trial; notably, egg counts were reduced by 99% 28 days after MSRB administration to both groups of calves. There were no significant differences in the number of eggs counted from the three groups of cows, probably because of the very low numbers of eggs encountered. Mean total worm burdens of principal calves (six per group) necropsied at trial termination indicated a 91% (P less than 0.01) reduction in Group T-2 and an 87% reduction (P less than 0.01) in Group T-3. Worm-free tracer calves were introduced onto pastures every 28 days to monitor availability of infective larvae. The mean number of worms recovered at necropsy from tracer calves that grazed with control cattle increased as the season progressed. However, the numbers of parasites recovered each month from mid-August through mid-October from tracers that grazed pastures with treated cattle were lower (P less than 0.05) than those levels displayed at trial initiation. In addition, the mean numbers of worms from treated group tracers were lower than from the controls for each necropsy period.(ABSTRACT TRUNCATED AT 400 WORDS)     

A field study comparing a pregrazing treatment with the morantel sustained release bolus with a strategic deworming program in first year grazing cattle

A field trial was designed to compare the efficacy of a pregrazing treatment with a morantel sustained release bolus and two strategic treatments of levamisole in the prevention and control of gastrointestinal parasitism in first year grazing cattle. The infection of calves, pasture contamination and the subsequent effects on performance were recorded.     

Efficacy of dichlorvos, fenbendazole, and ivermectin in swine with induced intestinal nematode infections

Anthelmintic efficacies of dichlorvos, fenbendazole, and ivermectin were compared in specific-pathogen-free crossbred weanling pigs inoculated with Ascaris suum, Trichuris suis, and Oesophagostomum dentatum. On postinoculation day (PID) 50, 24 pigs in each treatment group were treated orally with 43 mg of dichlorvos/kg of body weight, 3 X 3 mg of fenbendazole/kg, or 300 micrograms of ivermectin/kg, SC. Twenty-four pigs were not treated. On posttreatment day 7 (PID 57), 12 pigs from each treatment group (phase I) were slaughtered, and the anthelmintic efficacy of each treatment was determined. Efficacies against A suum, T suis, and O dentatum, respectively, were: dichlorvos, 100%, 99.9%, and 100%; fenbendazole, 100%, 99.8%, and 100%; and ivermectin, 98.7%, 53.9%, and 87.6%. Weight gains and feed conversions of the remaining pigs were monitored until they reached market weight (phase II). The average weight gains (kg) and feed conversions (kg of feed/kg of gain) at posttreatment day 81 (PID 131), respectively, were: 73.6 and 3.44 for nontreated controls, 78.9 and 3.31 for dichlorvos-treated pigs, 72.1 and 3.36 for fenbendazole-treated pigs, and 74 and 3.48 for ivermectin-treated pigs. Differences in average weight gains and feed conversions were not significant (P greater than 0.05).     

Persistence of ivermectin in plasma and faeces following administration of a sustained-release bolus to cattle

Six calves (weight 210 to 230 kg) were dosed with an intra-ruminal slow-release bolus prepared to deliver ivermectin at a low daily dosage for 135 days. Ivermectin concentrations in jugular blood 160 days post-treatment were determined by high performance liquid chromatography (HPLC) using fluorescence detection. Ivermectin plasma concentrations increased gradually to achieve the steady-state concentration (20 ng ml(-1)) at approximately four days post-treatment, which was maintained for 120 days. The ivermectin peak plasma concentration (28.5 ng ml(-1)) was attained at 15 days post-administration of the bolus. The faecal ivermectin concentration rose to a maximal concentration of 4.1 microg g(-1) at four days post-treatment, dropping to a steady-state concentration of around 1.18 microg g(-1) which was maintained up to 120 days post-treatment. Ivermectin was detected in both plasma (0.05 ng ml(-1)) and faeces (2.67 ng g(-1)) up to 160 days. The high levels of ivermectin recovered in faeces indicate that a large proportion of the dose released by the bolus (80 to 90 per cent) is excreted in faeces.